Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

By B. Cheson, Richard I. Fisher, Sally F. Barrington, F. Cavalli, Lawrence H. Schwartz, E. Zucca, T. Andrew Lister. Journal of Clinical Oncology, 2014

4,784 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ddb142ee4f9f01d76e57b8002b0bb7d690d53bb9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Chao
2. Irving L. Weissman
3. R. Majeti
4. L. Nastoupil
5. J. Volkmer
6. S. Neelapu
7. R. Advani
8. M. Jain

Citations in the corpus

• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma (2018, background): “‡ A Lugano stage of I indicates disease involving one lymph node or a group of adjacent nodes, II two or more nodal groups on the same side of the diaphragm, III nodes on both sides of the diaphragm or nodes above the diaphragm with spleen involvement, and IV additional noncontiguous extralymphatic ”
• Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2021, background): “Hypotension 75 (44) 19 (11) 25 (15) 5 (3)”
• Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. (2017, background): “Nodal responses are reported by International Workshop on Chronic Lymphocytic Leukemia (IWCLL; 2008) criteria, and when positron emission tomography (PET) imaging was available, by Cheson 2014 criteria (Appendix).(18,19) Marrow biopsies were obtained before lymphodepletion and 4 weeks after administ”
• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, methodology): “A new staging system that has not been prospectively validated has been recently proposed [20].”
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018, neutral): “Median age, years (IQR) 33 (26-45) 37 (28-48) 32 (25-47) 34 (26-46) $ 60 5 (8) 7 (9) 3 (3) 15 (6) Male 34 (54) 51 (64) 56 (56) 141 (58) ECOG PS 0 39 (62) 42 (53) 50 (50) 131 (54) 1 24 (38) 38 (48) 50 (50) 112 (46) Disease stage at study entry I 1 (2) 1 (1) 2 (2) 4 (2) II 20 (32) 11 (14) 20 (20) 51 (”
• Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. (2020, methodology): “Tumor response assessments were performed locally per Lugano 2014 classification.(13)”